Route to market, price, procurement access and a commercial organisation that can carry it. These decide whether advanced medical technology becomes a business — and they are built, not assumed.
Approval is a specification.
A market is built.
Senior commercial roles inside multinational and emerging medical-technology companies — Canadian business-unit P&L, North American business development and M&A, then a global upstream product roadmap.
Commercial market entry across the Canada–US border, from inside operating companies rather than advising from outside.
Surgical technology, infusion, diagnostics and digital health — each with its own procurement and access reality.
Most companies reach launch having engineered one column with total rigour and improvised the other under time pressure. The second column is where the revenue actually is.
Apex specifies the second column with the same rigour the first one already had.
The moments Apex gets called
“We have a product and a target country. How do we actually build the business there?”
Pre-launch · new geography
Route to market, channel economics, procurement strategy and launch sequencing for Canada and the United States.
“We’re cleared, we’re selling a little, and nothing is compounding.”
Post-clearance · flat revenue
Buying-process mapping, segmentation, pricing architecture and the clinical and economic case for switching.
“We need senior commercial leadership. We’re not ready to hire a full-time CCO.”
Capability gap · no senior owner
Embedded leadership — team design and hiring, territory architecture, distributor build, pipeline discipline.
“Does this market, this plan or this asset actually hold up?”
Transaction · board review
Independent commercial read for boards, acquirers and investors — including whether the sales capacity delivers the revenue plan.
If one of these is roughly where you are, that is the conversation to start with.
Market entry
Two countries, one border, two completely different commercial models. The regulatory path and the commercial path are not the same journey — and only one of them ends in revenue.
Regulatory entry
Permission to sell.
The path ends here.
Commercial entry — Apex
Revenue.
Apex is not a regulatory consultancy. Specialist regulatory and quality expertise is contracted when an engagement requires it, and coordinated so the regulatory path stays aligned to the commercial plan.
How we work
The analysis runs at machine speed. The judgement does not — and no output reaches a client without a senior operator having reviewed it.
Discuss a commercial challengeMark brought tremendous value as VP of Sales & Marketing — building structured sales processes, refining our market positioning, and elevating our external communications while leading the team day to day. He knows how to translate complex clinical technology into clear, compelling value propositions, and his ability to align marketing strategy with revenue objectives helped our company grow exponentially.
Apex held the fractional VP Sales & Marketing role at NeuroCatch, a Canadian neurodiagnostics company building its commercial organisation in the United States — covering team structure and hiring, territory design, distributor strategy and market segmentation.
Selected engagements
Engagements shown by category where the relationship is confidential. Further engagements are covered by confidentiality.
The practice
A clinician who moved into commercial roles, then spent more than two decades learning how medical technology actually gets bought — hospital contracting and corporate accounts, market development and reimbursement, and the Canadian launch of a surgical robotics platform.
Then nine years in senior commercial leadership at a global infusion-therapy manufacturer: a Canadian business unit run with full P&L responsibility, then North American business development and M&A, then a global upstream product roadmap.
Current industry developments, aggregated from public sources. Apex adds commercial interpretation selectively, not to every item.
Apex take
Longer authorization timelines matter commercially not only because they delay launch, but because they compress everything that follows. Procurement cycles, GPO windows, provincial funding processes and channel preparation do not move in step with regulators. The companies that navigate delay best are usually the ones building the commercial pathway in parallel, rather than waiting for clearance to begin.
Current feed
Headlines are aggregated from public industry sources and are not Apex research. Links resolve to the original publisher.
Next step
Tell us the market, the stage, and what is actually in the way.
What a first conversation is
Thirty minutes to understand the commercial problem and say plainly whether Apex is the right fit — and who else might be, if not. No deck, no proposal, no obligation. Mark takes these himself and replies within one business day.